#USA #Baltimore #CDI Labs #HuProt #VirScan

CDI Labs Launches Innovative Pan-isotype Analysis

CDI Labs Inc., a leading name in the field of proteome-wide antibody profiling, has recently announced the roll-out of its new Pan-isotype Analysis Platform. This advanced service is poised to make significant strides in the research of serum autoantibodies by offering the ability to scrutinize all antibody isotypes and subclasses. With access to over 80% of the human proteome through their HuProt™ microarray and comprehensive virus profiles via VirScan®, researchers can gain unprecedented insights into humoral immunity.

Breaking New Ground in Antibody Profiling

Traditionally, investigations into serum autoantibodies have focused on pan-IgG analysis, which identifies the IgG subclasses collectively, without differentiating among the four (IgG1, IgG2, IgG3, and IgG4). Although this method has yielded valuable data, it captures just a fraction of the entire humoral immune response encapsulated in serum samples. Each IgG subclass, as well as other isotypes like IgA, IgD, IgE, and IgM, carries unique structural attributes that significantly influence their roles in immune function.

Barney Saunders, CEO of CDI Labs, remarked, "We're at an exciting juncture in autoantibody research. Understanding the immune response is crucial, and our new capabilities provide a more nuanced view of the various isotypes and subclasses involved in this process. By combining our pan-isotype analysis with high-throughput technologies, we are equipped to facilitate deeper explorations into antibody diversity."

The New Pan-Isotype Analysis Features

The Pan-isotype Analysis Platform opens up new avenues of research. CDI Labs now provides profiling services that can detect a wide range of antibodies, including:

• - Pan-IgA (both IgA1 and IgA2)
• - IgD, IgE, and IgM
• - Pan-IgG (which encompasses IgG1 through IgG4) as well as individual subclass analysis for discerning shifts in abundance that could indicate disease trends.

This capability means researchers can zero in on the intricate details of how the immune system reacts to different pathogens, ultimately linking antibody diversity to specific health outcomes.

Advanced Proteomics Technology

CDI's HuProt™ services leverage a highly validated protein array comprising over 21,000 carefully curated, folded, and purified proteins, representing an extensive slice of the human proteome. Simultaneously, the VirScan® technology utilizes phage display immunoprecipitation sequencing (PhIP-Seq) to conduct epitope-level antibody profiling against a variety of vertebrate viral proteomes.

This potent combination allows researchers to conduct multiplexed analyses and gain crucial insights into the immune response to both autoantigens and pathogens, opening the door to better diagnostics and therapeutic strategies.

Moving Forward in Autoantibody Research

As researchers continue to seek more nuanced data regarding their subjects' immune profiles, the relevance of CDI Labs’ new offerings cannot be overstated. The shift from traditional, generalized approaches to more detailed profiling has the potential to enhance our understanding of autoimmune diseases, infectious disease susceptibility, and much more.

CDI Labs has established itself as a key player in the realm of proteomics and continues to innovate with a dedication to aiding researchers across different fields. Their commitment to advancing scientific knowledge through cutting-edge technology ensures a bright future for health and wellness advancements based on a deeper understanding of the human immune response.

In a world increasingly focused on personalized medicine, the data derived from CDI Labs’ Pan-isotype Analysis will be invaluable for pioneering research and development efforts. For those interested in these advanced services, further information can be found on the CDI Labs website.

About CDI Laboratories, Inc.

CDI Labs is a specialized contract research organization (CRO) that provides a myriad of lab services focusing on proteomics. Through the use of advanced synthetic biology methods, the company holds the title of having the most extensive collection of proteomes, alongside a dedicated team proficient in the nuances of proteomics. Their service offerings span various research phases, empowering clients to uncover molecular interactions effectively across vast datasets.

For inquiries, please reach out through the official website or contact their media representative directly.